1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
GLP-1 receptor agonists move from weight loss into the longevity conversation GLP-1 receptor agonists are quickly shifting from niche metabolic ...
1. Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food or timing ...
